MapLight Therapeutics, Inc. (MPLT)
$7.88-8.37%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6M
- Beta
- 2.77
- P/E (TTM)
- -1.52
- Short % float
- 1048.35%
- Days to cover
- 5.8
- SI change
- -4.5%
- 1W
- -18.68%
- 1M
- -40.08%
- vs SPY 1W
- -18.54%
- vs SPY 1M
- -42.58%
Industry peers
FMP comparable companies · ranked by market cap
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90-2.33%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 24$30.65-3.85%
- GHRSSELLGH Research PLC$1.4BCRISISQ 14$21.11-5.84%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$1.1BCRISISQ 75$37.22-3.17%
- ANROSELLAlto Neuroscience, Inc.$855MCRISISQ 15$24.37-8.53%
- ZVRASELLZevra Therapeutics, Inc.$673MCRISISQ -8$11.39-8.22%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on MPLT?
- LOPJLB’s latest quantitative signal on MapLight Therapeutics, Inc. (MPLT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MPLT in?
- MapLight Therapeutics, Inc. (MPLT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MapLight Therapeutics, Inc. (MPLT) do?
- MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer'…